Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Main Treatment Phase (MT)	STARTED	Riociguat (Adempas, BAY63-2521)	60
Main Treatment Phase (MT)	STARTED	Placebo	61
Main Treatment Phase (MT)	COMPLETED	Riociguat (Adempas, BAY63-2521)	42
Main Treatment Phase (MT)	COMPLETED	Placebo	46
Main Treatment Phase (MT)	NOT COMPLETED	Riociguat (Adempas, BAY63-2521)	18
Main Treatment Phase (MT)	NOT COMPLETED	Placebo	15
Long-term Extension Phase (LTE)	STARTED	Riociguat (Adempas, BAY63-2521)	42
Long-term Extension Phase (LTE)	STARTED	Placebo	45
Long-term Extension Phase (LTE)	COMPLETED	Riociguat (Adempas, BAY63-2521)	32
Long-term Extension Phase (LTE)	COMPLETED	Placebo	31
Long-term Extension Phase (LTE)	NOT COMPLETED	Riociguat (Adempas, BAY63-2521)	10
Long-term Extension Phase (LTE)	NOT COMPLETED	Placebo	14

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02283762/flow